Abcuro Inc.
- Address
- 55 Chapel Street Suite 200
Sponsor Overview
Specializations
Oncology and Cancer Therapeutics
Abcuro Inc. demonstrates a concentrated focus on developing innovative treatments for hematologic malignancies, with particular emphasis on addressing challenging forms of blood cancers. The company's research portfolio targets patients with relapsed or refractory disease, representing a critical unmet medical need where conventional therapies have proven insufficient.
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)
- Chronic Myelomonocytic Leukemia (CMML)
The therapeutic strategy encompasses interventions for patients who have experienced disease progression following standard treatment regimens, including those with prior exposure to hypomethylating agents. This research direction addresses a patient population with limited therapeutic options and represents an area of significant clinical challenge in contemporary hematology.
Immunotherapy and Targeted Biological Interventions
The company's investigational programs center on novel immunotherapeutic approaches designed to harness the body's immune system against cancer cells. Research activities explore mechanisms that may enhance immune recognition and elimination of malignant cells in blood-based cancers.
- Immune-mediated cancer cell targeting
- Biological response modulation
- Advanced therapeutic protein development
These investigations reflect a commitment to advancing precision medicine strategies in hematologic oncology, with particular attention to patient populations who have exhausted conventional treatment pathways and require innovative therapeutic alternatives.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis |  Belgium France Germany | Not Recruiting |
| Long-term Safety and Efficacy Evaluation of Ulviprubart (ABC008) in Patients with Inclusion Body Myositis Following Completion of Prior Ulviprubart Trials | Belgium France Germany | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 5 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases2 trials238 other sponsors
Partnered Research Centres
5 centres- Address
- Groenebriel 1, 9000 Ghent
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- Seebad 82/83, 15562 Rüdersdorf
- Address
- Moorenstrasse 5, Bilk, 40225 Düsseldorf
- Address
- 47 To 83 Boulevard De L Hopital, 75013 Paris
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Abcuro Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.